Irreversible Electroporation - Medicare Advantage

This policy addresses irreversible electroporation (IRE) procedures (eg, NanoKnife, Aliya systems) for tumor ablation in cancers including prostate, pancreatic, primary and metastatic liver, kidney, and colorectal liver metastases. However, IRE is considered investigational/not medically reasonable and necessary for any indication due to insufficient, low‑quality evidence, lack of guideline endorsement and demonstrated benefit versus established ablative therapies (FDA clearance is for soft‑tissue ablation generally, not specific tumor indications), and therefore is excluded from coverage.

"No limitations, exclusions, frequency limits, patient criteria, or non-covered situations are specified in the provided document excerpt."

Sign up to see full coverage criteria, indications, and limitations.